G17DT + gemcitabine

G17DT + gemcitabine is a **combination therapy** being investigated for the treatment of advanced pancreatic and gastric cancer, combining the **G17DT immunogen** (a peptide-conjugate therapeutic vaccine targeting gastrin 17) with **gemcitabine** (a cytotoxic nucleoside analog chemotherapy). **G17DT** is designed to elicit antibodies against gastrin 17 and glycine-extended gastrin, blocking their growth-promoting effects at the cholecystokinin-2 (CCK-B) receptor in gastrointestinal cancers. When combined with gemcitabine, the intent is to leverage the immune modulation of G17DT with the cytotoxicity of gemcitabine. Clinical studies include phase III trials in advanced pancreatic cancer, specifically G17DT + gemcitabine vs. placebo + gemcitabine. Evidence suggests combination immunotherapy/chemotherapy may benefit patients with high anti-gastrin antibody titers, though no consistent survival benefit was seen in unselected populations[3][5][6].

Brand names

Gastrimmune

Other names

anti-gastrin 17 immunogen + gemcitabineG17DT immunogen + gemcitabineGastrin 17 vaccine + gemcitabinegastrin 17C diphtheria toxoid immunogen + gemcitabine